The effects of obesity on drug pharmacokinetics in humans

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 6, 2011, Pages 697-706

  Morrish, Glynn A ^a   Pai, Manjunath P ^b   Green, Bruce ^a  

^a Model Answers Pty Ltd   (Australia)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

dosing; lean body weight; obesity; pharmacokinetics

Indexed keywords

BODY COMPOSITION; BODY WEIGHT; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; OBESITY; ORGAN WEIGHT; PHARMACOKINETICS; REVIEW;

BODY COMPOSITION; BODY MASS INDEX; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; OBESITY; ORGAN SIZE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHYSIOLOGICAL PHENOMENA;

EID: 79956155336     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.570331     Document Type: Review

References (88)

1. World Health Organization. Obesity and overweight. Fact Sheet 311 2006
2. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001; 9:(Suppl 4):326S-334S
3. National Institute of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. US Department of Health and Human Services, Bethesda, MD; 1998
4. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health 2007;121(7):492-6 (Pubitemid 46895458)
5. Martinez M, Mahmood I, Hunter RP. Allometric scaling of clearance in dogs. J Vet Pharmacol Ther 2009;32(5):411-16
6. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 2009;157(6):907-21
7. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004;58(2):119-33 (Pubitemid 39043992)
8. Chiba M, Ishii Y, Sugiyama Y. Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 2009;11(2):262-76
9. Feng B, LaPerle JL, Chang G, Varma MV. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state. Expert Opin Drug Metab Toxicol 2010;6(8):939-52
10. Forbes GB, Welle SL. Lean body mass in obesity. Int J Obes 1983;7(2):99-107 (Pubitemid 13097059)
11. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999;88(1):1-7 (Pubitemid 29037361)
12. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000;39(3):215-31
13. Lemmens HJ. Perioperative pharmacology in morbid obesity. Curr Opin Anaesthesiol 2010;23(4):485-91
14. Han PY, Kirkpatrick CM, Green B. Informative study designs to identify true parameter-covariate relationships. J Pharmacokinet Pharmacodyn 2009;36(2):147-63
15. Young JF, Luecke RH, Pearce BA, et al. Human organ/tissue growth algorithms that include obese individuals and black/ white population organ weight similarities from autopsy data. J Toxicol Environ Health A 2009;72(8):527-40
16. de la Grandmaison GL, Clairand I, Durigon M. Organ weight in 684 adult autopsies: new tables for a Caucasoid population. Forensic Sci Int 2001;119(2):149-54 (Pubitemid 32455488)
17. Ogiu N, Nakamura Y, Ijiri I, et al. A statistical analysis of the internal organ weights of normal Japanese people. Health Phys 1997;72(3):368-83 (Pubitemid 27086005)
18. Singh D, Bansal YS, Sreenivas M, et al. Weights of human organs at autopsy in Chandigarh zone of North-west India. J Indian Assoc Forens Med 2004;26:97-9
19. Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev 1991;49(6):163-75
20. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005;44(10):1051-65 (Pubitemid 41356391)
21. Nawaratne S, Brien JE, Seeman E, et al. Relationships among liver and kidney volumes, lean body mass and drug clearance. Br J Clin Pharmacol 1998;46(5):447-52 (Pubitemid 28484731)
22. Han PY, Duffull SB, Kirkpatrick CM, Green B. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007;82(5):505-8 (Pubitemid 47622534)
23. McLeay SC, Morrish GA, Kirkpatrick CM, Green B. Encouraging the move towards predictive population models for the obese using propofol as a motivating example. Pharm Res 2009;26(7):1626-34
24. Pietilainen KH, Rissanen A, Kaprio J, et al. Acquired obesity is associated with increased liver fat, intra-abdominal fat, and insulin resistance in young adult monozygotic twins. Am J Physiol Endocrinol Metab 2005;288(4):E768-74 (Pubitemid 40397213)
25. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121(1):91-100 (Pubitemid 32591518)
26. Rinella ME, Alonso E, Rao S, et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl 2001;7(5):409-14 (Pubitemid 32492578)
27. Feldschuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977;56(4 Pt 1):605-12
28. Lemmens HJ, Bernstein DP, Brodsky JB. Estimating blood volume in obese and morbidly obese patients. Obes Surg 2006;16(6):773-6 (Pubitemid 43874836)
29. Jansson PA, Larsson A, Lonnroth PN. Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1998;28(10):813-18 (Pubitemid 28488114)
30. Summers LK, Samra JS, Humphreys SM, et al. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 1996;91(6):679-83 (Pubitemid 26413821)
31. Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci 1993;306(2):117-23 (Pubitemid 23242737)
32. Chinali M, Devereux RB, Howard BV, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 2004;93(1):40-4 (Pubitemid 38028620)
33. Collis T, Devereux RB, Roman MJ, et al. Relations of stroke volume and cardiac output to body composition: the strong heart study. Circulation 2001;103(6):820-5 (Pubitemid 32163879)
34. Luecke RH, Pearce BA, Wosilait WD, et al. Postnatal growth considerations for PBPK modeling. J Toxicol Environ Health A 2007;70(12):1027-37 (Pubitemid 46752498)
35. Alexander JK, Dennis EW, Smith WG, et al. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull 1962;1:39-44
36. Danias PG, Tritos NA, Stuber M, et al. Cardiac structure and function in the obese: a cardiovascular magnetic resonance imaging study. J Cardiovasc Magn Reson 2003;5(3):431-8 (Pubitemid 36859426)
37. de Simone G, Devereux RB, Daniels SR, et al. Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight. Circulation 1997;95(7):1837-43
38. Messerli FH, Ventura HO, Reisin E, et al. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation 1982;66(1):55-60 (Pubitemid 12069957)
39. Palmieri V, de Simone G, Arnett DK, et al. Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study). Am J Cardiol 2001;88(10):1163-8 (Pubitemid 33043851)
40. Stelfox HT, Ahmed SB, Ribeiro RA, et al. Hemodynamic monitoring in obese patients: the impact of body mass index on cardiac output and stroke volume. Crit Care Med 2006;34(4):1243-6
41. Albertin A, Poli D, La Colla L, et al. Predictive performance of 'Servin's formula' during BIS-guided propofolremifentanil target-controlled infusion in morbidly obese patients. Br J Anaesth 2007;98(1):66-75 (Pubitemid 44896753)
42. La Colla L, La Colla G, Albertin A, et al. The use of propofol and remifentanil for the anaesthetic management of a super-obese patient. Anaesthesia 2007;62(8):842-5 (Pubitemid 47103638)
43. Barras MA, Duffull SB, Atherton JJ, Green B. Individualized compared with conventional dosing of enoxaparin. Clin Pharmacol Ther 2008;83(6):882-8 (Pubitemid 351704919)
44. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49(2):71-87
45. Keys A, Fidanza F, Karvonen MJ, et al. Indices of relative weight and obesity. J Chronic Dis 1972;25(6):329-43
46. Du Bois D, Du Bois EF. Clinical calorimetry. Tenth paper. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863
47. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987;317(17):1098
48. Devine D. Case study number 25 gentamicin therapy. Drug Intell Clin Pharm 1974;8:650-5
49. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol 1988;6(8):1321-7
50. Duffull SB, Dooley MJ, Green B, et al. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004;43(15):1167-78 (Pubitemid 40013182)
51. James W. Research on Obesity. London: Her Majesty's Stationery Office 1976
52. Green B, Duffull S. Caution when lean body weight is used as a size descriptor for obese subjects. Clin Pharmacol Ther 2002;72(6):743-4 (Pubitemid 36021015)
53. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 2002;42(6):620-43 (Pubitemid 34547446)
54. Jung D, Mayersohn M, Perrier D, et al. Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology 1982;56(4):269-74
55. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005;45(1):48-56
56. Pai MP, Norenberg JP, Anderson T, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007;51(8):2741-7 (Pubitemid 47206208)
57. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72(3):308-18
58. Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007;25(30):4707-13 (Pubitemid 350086471)
59. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 1994;26(4):292-307
60. Abernethy DR, Greenblatt DJ. Phenytoin disposition in obesity. Determination of loading dose. Arch Neurol 1985;42(5):468-71
61. Abernethy DR, Greenblatt DJ, Divoll M, et al. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet 1984;9(2):177-83 (Pubitemid 14164708)
62. Benedek IH, Blouin RA, McNamara PJ. Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 1984;18(6):941-6 (Pubitemid 15190533)
63. Derry CL, Kroboth PD, Pittenger AL, et al. Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. J Clin Psychopharmacol 1995;15(3):197-205
64. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009;20(11):2305-13
65. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983;24(5):643-7 (Pubitemid 13092243)
66. Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol Renal Physiol 2008;294(4):F685-96
67. Chagnac A, Herman M, Zingerman B, et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 2008;23(12):3946-52
68. Blackburn GL, Hutter MM, Harvey AM, et al. Expert panel on weight loss surgery: executive report update. Obesity (Silver Spring) 2009;17(5):842-62
69. Navarro-Diaz M, Serra A, Romero R, et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 2006;17(12 Suppl 3):S213-7 (Pubitemid 44865251)
70. Saliba J, Kasim NR, Tamboli RA, et al. Roux-en-Y gastric bypass reverses renal glomerular but not tubular abnormalities in excessively obese diabetics. Surgery 147(2):282-7
71. Serpa Neto A, Bianco Rossi FM, Dal Moro Amarante R, et al. Effect of weight loss after Roux-en-Y gastric bypass, on renal function and blood pressure in morbidly obese patients. J Nephrol 2009;22(5):637-46
72. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009;66(7):642-8
73. Ozmen S, Kaplan MA, Kaya H, et al. Role of lean body mass for estimation of glomerular filtration rate in patients with chronic kidney disease with various body mass indices. Scand J Urol Nephrol 2009;43(2):171-6
74. Pai MP. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 2010;17(5):e53-62
75. Green B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003;56(1):96-103 (Pubitemid 36886494)
76. Ekhart C, Rodenhuis S, Schellens JH, et al. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? Cancer Chemother Pharmacol 2009;64(1):115-22
77. Schmitt A, Gladieff L, Lansiaux A, et al. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 2009;15(10):3633-9
78. Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochem J 2010;429(3):435-49
79. Sissung TM, Baum CE, Kirkland CT, et al. Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 2010;44(2):152-67
80. Abernethy DR, Greenblatt DJ. Drug disposition in obese humans. An update. Clin Pharmacokinet 1986;11(3):199-213
81. Videau O, Delaforge M, Levi M, et al. Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. Rapid Commun Mass Spectrom 2010;24(16):2407-19
82. La Colla L, Albertin A, La Colla G, et al. Predictive performance of the 'Minto' remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass. Clin Pharmacokinet 2010;49(2):131-9
83. Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003;38(2):428-35 (Pubitemid 36919864)
84. Leclercq I, Horsmans Y, Desager JP, et al. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J Hepatol 1998;28(3):410-16 (Pubitemid 28133544)
85. Su GM, Sefton RM, Murray M. Down-regulation of rat hepatic microsomal cytochromes P-450 in microvesicular steatosis induced by orotic acid. J Pharmacol Exp Ther 1999;291(3):953-9
86. Donato MT, Jimenez N, Serralta A, et al. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol In Vitro 2007;21(2):271-6 (Pubitemid 46205072)
87. Donato MT, Lahoz A, Jimenez N, et al. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 2006;34(9):1556-62 (Pubitemid 44285398)
88. Greenman CG, Jagielski CH, Griggs JJ. Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice. Cancer 2008;112(10):2159-65 (Pubitemid 351628624)